{"id":1467,"date":"2026-04-01T06:47:46","date_gmt":"2026-04-01T06:47:46","guid":{"rendered":"https:\/\/kishiwada.tokushukai.or.jp\/en\/research\/publications\/yutaka-yonemura\/"},"modified":"2026-04-11T03:56:08","modified_gmt":"2026-04-11T03:56:08","slug":"yutaka-yonemura","status":"publish","type":"page","link":"https:\/\/kishiwada.tokushukai.or.jp\/en\/research\/publications\/yutaka-yonemura\/","title":{"rendered":"Publications \u2014 Yutaka Yonemura MD PhD"},"content":{"rendered":"<p><!-- ============================================================\n     Publications \u2014 Yutaka Yonemura MD PhD\n     URL: \/en\/research\/publications\/yutaka-yonemura\/\n     WordPress H1: Publications \u2014 Yutaka Yonemura MD PhD\n     ============================================================ --><\/p>\n<section class=\"op-section\">\n<p class=\"page-lead\">Peer-reviewed publications by <strong>Yutaka Yonemura, M.D., Ph.D.<\/strong> (\u7c73\u6751 \u8c4a), specialist in peritoneal surface oncology at Kishiwada Tokushukai Hospital. L-HIPEC papers are listed first within each section.<\/p>\n<p style=\"margin-top:0.5rem;\"><a href=\"\/en\/departments\/peritoneal-surface-oncology\/\">\u2190 Dr. Yonemura&#8217;s clinical page<\/a><\/p>\n<nav class=\"page-nav\" aria-label=\"On this page\">\n<ul class=\"page-nav-list\">\n<li><a href=\"#gastric\">Gastric Cancer<\/a><\/li>\n<li><a href=\"#colorectal\">Colorectal Cancer<\/a><\/li>\n<li><a href=\"#ovarian\">Ovarian Cancer<\/a><\/li>\n<li><a href=\"#pmp\">Pseudomyxoma Peritonei<\/a><\/li>\n<li><a href=\"#mesothelioma\">Peritoneal Mesothelioma<\/a><\/li>\n<li><a href=\"#pioneer\">Pioneer &amp; JASPSO<\/a><\/li>\n<\/ul>\n<\/nav>\n<section id=\"gastric\" class=\"op-section\">\n<h2>Gastric Cancer<\/h2>\n<ul class=\"pub-list\">\n<li>Yonemura Y, Ishibashi H et al.<br \/>\n        <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/27506661\/\" target=\"_blank\" rel=\"noopener\">Effects of neoadjuvant laparoscopic HIPEC + NIPS on peritoneal metastases from gastric cancer.<\/a><br \/>\n        <em>Ann Surg Oncol<\/em> 2017. \u00b7 Kishiwada Tokushukai Hospital. \u00b7 53 patients.<\/li>\n<li>Yu HH, Yonemura Y et al.<br \/>\n        <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37444511\/\" target=\"_blank\" rel=\"noopener\">Neoadjuvant L-HIPEC + BISIC bidirectional chemotherapy for gastric cancer peritoneal metastases.<\/a><br \/>\n        <em>Cancers (Basel)<\/em> 2023. \u00b7 113 patients.<\/li>\n<li>Yonemura Y et al. (PSOGI)<br \/>\n        <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/27160355\/\" target=\"_blank\" rel=\"noopener\">Comprehensive treatment for gastric cancer peritoneal metastases with curative intent \u2014 PSOGI consensus.<\/a><br \/>\n        <em>Eur J Surg Oncol<\/em> 2016.<\/li>\n<li>Brandl A, Yonemura Y, Glehen O, Sugarbaker PH, Rau B.<br \/>\n        <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33071173\/\" target=\"_blank\" rel=\"noopener\">Long-term survival (&gt;5 years) after CRS + HIPEC for gastric peritoneal metastases \u2014 PSOGI multi-institutional cohort.<\/a><br \/>\n        <em>Eur J Surg Oncol<\/em> 2021.<\/li>\n<li>Prabhu A, Mishra D, Brandl A, Yonemura Y.<br \/>\n        <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35719946\/\" target=\"_blank\" rel=\"noopener\">Gastric cancer with peritoneal metastases \u2014 comprehensive review of intraperitoneal treatment modalities.<\/a><br \/>\n        <em>Front Oncol<\/em> 2022.<\/li>\n<li>Yonemura Y, Liu Y, Sugarbaker PH, Li Y.<br \/>\n        <a href=\"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/02656736.2017.1283065\" target=\"_blank\" rel=\"noopener\">Current status and future prospects of clinical trials on CRS + HIPEC for gastric peritoneal metastases.<\/a><br \/>\n        <em>Int J Hyperthermia<\/em> 2017.<\/li>\n<\/ul>\n<\/section>\n<section id=\"colorectal\" class=\"op-section\">\n<h2>Colorectal Cancer<\/h2>\n<ul class=\"pub-list\">\n<li>Arjona-S\u00e1nchez \u00c1, Yonemura Y et al.<br \/>\n        <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0748798321001530\" target=\"_blank\" rel=\"noopener\">Laparoscopic CRS + HIPEC for limited peritoneal metastasis \u2014 PSOGI international registry (143 patients).<\/a><br \/>\n        <em>Eur J Surg Oncol<\/em> 2021. \u00b7 88.2% disease-free.<\/li>\n<li>Yonemura Y et al.<br \/>\n        <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3654240\/\" target=\"_blank\" rel=\"noopener\">Prognostic factors after CRS + perioperative chemotherapy for colorectal peritoneal metastases \u2014 142 patients.<\/a><br \/>\n        <em>Scientific World Journal<\/em> 2013. \u00b7 Open Access.<\/li>\n<li>van de Vlasakker VCJ, \u2026 Yonemura Y, Glehen O et al.<br \/>\n        <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34020808\/\" target=\"_blank\" rel=\"noopener\">Impact of PRODIGE 7 on CRS-HIPEC worldwide \u2014 PSOGI 2021 statement.<\/a><br \/>\n        <em>Eur J Surg Oncol<\/em> 2021.<\/li>\n<\/ul>\n<\/section>\n<section id=\"ovarian\" class=\"op-section\">\n<h2>Ovarian Cancer<\/h2>\n<ul class=\"pub-list\">\n<li>Arjona-S\u00e1nchez \u00c1, Yonemura Y et al.<br \/>\n        <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0748798321001530\" target=\"_blank\" rel=\"noopener\">Laparoscopic CRS + HIPEC \u2014 includes ovarian cancer cases (PSOGI international registry).<\/a><br \/>\n        <em>Eur J Surg Oncol<\/em> 2021.<\/li>\n<li>Canbay Torun B, \u2026 Yonemura Y et al.<br \/>\n        <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0748798323005267\" target=\"_blank\" rel=\"noopener\">Peritoneal metastasis of advanced epithelial ovarian carcinoma treated with CRS + HIPEC \u2014 international multicentric analysis.<\/a><br \/>\n        <em>Eur J Surg Oncol<\/em> 2023.<\/li>\n<\/ul>\n<\/section>\n<section id=\"pmp\" class=\"op-section\">\n<h2>Pseudomyxoma Peritonei &amp; Appendiceal Cancer<\/h2>\n<ul class=\"pub-list\">\n<li>Arjona-S\u00e1nchez \u00c1, Yonemura Y et al.<br \/>\n        <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0748798321001530\" target=\"_blank\" rel=\"noopener\">Laparoscopic CRS + HIPEC \u2014 pseudomyxoma peritonei is the most frequent indication (55% of 143 cases).<\/a><br \/>\n        <em>Eur J Surg Oncol<\/em> 2021. \u00b7 88.2% disease-free.<\/li>\n<li>Govaerts K, \u2026 Yonemura Y et al.<br \/>\n        <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0748798320312348\" target=\"_blank\" rel=\"noopener\">Appendiceal tumours and pseudomyxoma peritonei \u2014 PSOGI\/EURACAN clinical practice guidelines.<\/a><br \/>\n        <em>Eur J Surg Oncol<\/em> 2021.<\/li>\n<\/ul>\n<\/section>\n<section id=\"mesothelioma\" class=\"op-section\">\n<h2>Peritoneal Mesothelioma<\/h2>\n<ul class=\"pub-list\">\n<li>Arjona-S\u00e1nchez \u00c1, Yonemura Y et al.<br \/>\n        <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0748798321001530\" target=\"_blank\" rel=\"noopener\">Laparoscopic CRS + HIPEC \u2014 includes multicystic mesothelioma (14% of PSOGI registry cases).<\/a><br \/>\n        <em>Eur J Surg Oncol<\/em> 2021.<\/li>\n<li>Kusamura S, \u2026 Yonemura Y et al.<br \/>\n        <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0748798320312348\" target=\"_blank\" rel=\"noopener\">Peritoneal mesothelioma \u2014 PSOGI\/EURACAN clinical practice guidelines.<\/a><br \/>\n        <em>Eur J Surg Oncol<\/em> 2021.<\/li>\n<\/ul>\n<\/section>\n<section id=\"pioneer\" class=\"op-section\">\n<h2>Pioneer &amp; JASPSO<\/h2>\n<ul class=\"pub-list\">\n<li>Yonemura Y et al.<br \/>\n        <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/30886486\/\" target=\"_blank\" rel=\"noopener\">History of peritoneal surface malignancy treatment in Japan \u2014 JASPSO founding and global training programme.<\/a><br \/>\n        <em>PMC<\/em> 2019. \u00b7 JASPSO director \u00b7 16 international surgeons trained.<\/li>\n<li>Yonemura Y, Ishibashi H et al.<br \/>\n        <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32783786\/\" target=\"_blank\" rel=\"noopener\">Advances with pharmacotherapy for peritoneal metastasis.<\/a><br \/>\n        <em>Expert Opin Pharmacother<\/em> 2020. \u00b7 Kishiwada Tokushukai Hospital.<\/li>\n<\/ul>\n<\/section>\n<section class=\"op-section\">\n<h2>Data note<\/h2>\n<p>This list is compiled from publications provided by the department and may be updated periodically. Where available, items include direct links to PubMed, PMC, or journal pages.<\/p>\n<\/section>\n<\/section>\n<p><script type=\"application\/ld+json\">\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@graph\": [\n    {\n      \"@type\": \"MedicalWebPage\",\n      \"url\": \"https:\/\/kishiwada.tokushukai.or.jp\/en\/research\/publications\/yutaka-yonemura\/\",\n      \"name\": \"Publications \u2014 Yutaka Yonemura MD PhD | Kishiwada Tokushukai Hospital\",\n      \"description\": \"Peer-reviewed publications by Yutaka Yonemura M.D. Ph.D., specialist in laparoscopic HIPEC and peritoneal surface oncology at Kishiwada Tokushukai Hospital, Osaka.\",\n      \"inLanguage\": \"en\",\n      \"keywords\": \"Yonemura publications, laparoscopic HIPEC publications, peritoneal metastases research Japan, PSOGI Yonemura, CRS HIPEC gastric cancer\"\n    }\n  ]\n}\n<\/script><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Peer-reviewed publications by Yutaka Yonemura, M.D., Ph.D. (\u7c73\u6751 \u8c4a), specialist in peritoneal surface oncology at Kishiwada Tokushukai Hospital. L-HIPEC papers are listed first within each section. \u2190 Dr. Yonemura&#8217;s clinical page Gastric Cancer Colorectal Cancer Ovarian Cancer Pseudomyxoma Peritonei Peritoneal Mesothelioma Pioneer &amp; JASPSO Gastric Cancer Yonemura Y, Ishibashi H et al. Effects of neoadjuvant [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":942,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-1467","page","type-page","status-publish","hentry"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/kishiwada.tokushukai.or.jp\/en\/wp-json\/wp\/v2\/pages\/1467","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kishiwada.tokushukai.or.jp\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/kishiwada.tokushukai.or.jp\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/kishiwada.tokushukai.or.jp\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kishiwada.tokushukai.or.jp\/en\/wp-json\/wp\/v2\/comments?post=1467"}],"version-history":[{"count":4,"href":"https:\/\/kishiwada.tokushukai.or.jp\/en\/wp-json\/wp\/v2\/pages\/1467\/revisions"}],"predecessor-version":[{"id":1670,"href":"https:\/\/kishiwada.tokushukai.or.jp\/en\/wp-json\/wp\/v2\/pages\/1467\/revisions\/1670"}],"up":[{"embeddable":true,"href":"https:\/\/kishiwada.tokushukai.or.jp\/en\/wp-json\/wp\/v2\/pages\/942"}],"wp:attachment":[{"href":"https:\/\/kishiwada.tokushukai.or.jp\/en\/wp-json\/wp\/v2\/media?parent=1467"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}